Free Trial

Gabelli Funds LLC Sells 4,590 Shares of Merck & Co., Inc. $MRK

Merck & Co., Inc. logo with Medical background

Key Points

  • Gabelli Funds LLC reduced its stake in Merck & Co., Inc. by 1.3%, now holding 349,615 shares valued at approximately $31.38 million.
  • Merck's stock has seen a 2.2% decline, with its current price at $85.43, and its market cap stands at $213.39 billion.
  • The company recently declared a quarterly dividend of $0.81 per share, providing an annualized yield of 3.8% for shareholders.
  • Looking to export and analyze Merck & Co., Inc. data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Gabelli Funds LLC reduced its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.3% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 349,615 shares of the company's stock after selling 4,590 shares during the quarter. Gabelli Funds LLC's holdings in Merck & Co., Inc. were worth $31,381,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MRK. Barnes Dennig Private Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $27,000. Spurstone Advisory Services LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at $37,000. MorganRosel Wealth Management LLC bought a new stake in Merck & Co., Inc. in the first quarter valued at $36,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $44,000. Finally, Minot DeBlois Advisors LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter valued at about $45,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MRK has been the subject of several research reports. Cantor Fitzgerald downgraded Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday, May 20th. Morgan Stanley cut their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 30th. Finally, Citigroup restated a "neutral" rating and set a $84.00 price objective (down previously from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Hold" and an average target price of $107.44.

Read Our Latest Report on MRK

Merck & Co., Inc. Stock Down 1.0%

Shares of Merck & Co., Inc. stock traded down $0.84 on Thursday, hitting $83.24. The company had a trading volume of 14,481,452 shares, compared to its average volume of 11,252,589. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $120.30. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a 50 day moving average of $82.04 and a 200-day moving average of $83.02. The stock has a market capitalization of $207.90 billion, a price-to-earnings ratio of 12.83, a P/E/G ratio of 0.89 and a beta of 0.38.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $15.81 billion for the quarter, compared to analysts' expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.9%. Merck & Co., Inc.'s dividend payout ratio is presently 49.92%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines